68 results on '"Nishihori, Taiga"'
Search Results
2. Role of reduced intensity conditioning in allogeneic hematopoietic cell transplantation for patients with multiple myeloma
- Author
-
Nishihori, Taiga, Kharfan-Dabaja, Mohamed A., Ochoa-Bayona, Jose L., Bazarbachi, Ali, Pasquini, Marcelo, and Alsina, Melissa
- Published
- 2011
- Full Text
- View/download PDF
3. Adding Cyclophosphamide to Bortezomib and Dexamethasone was not Associated With Improved Outcomes of Patients With Newly Diagnosed Light Chain Amyloidosis: A Retrospective Study.
- Author
-
Zhang, Yumeng, Duncanson, Lauren, Brayer, Jason, Reu, Frederic, Hansen, Doris, Alsina, Melissa, Nishihori, Taiga, Ochoa-Bayona, Jose, Liu, Hien, Shain, Kenneth, Thompson, Zachary, Baz, Rachid, and Blue, Brandon
- Published
- 2022
- Full Text
- View/download PDF
4. The Application of NextGen Sequencing in the Diagnosis of Myeloid Neoplasms in Myeloma Patients With Cytopenia.
- Author
-
Song, Jinming, Zhang, Hailing, Dong, Ning, Zhang, Xiaohui, Hussaini, Mohammad, Jain, Akriti, Moscinski, Lynn, Shain, Ken, Baz, Rachid, Alsina, Melissa, Nishihori, Taiga, and Zhang, Ling
- Published
- 2022
- Full Text
- View/download PDF
5. Safety and efficacy of anti-BCMA CAR-T cell therapy in older adults with multiple myeloma: A systematic review and meta-analysis.
- Author
-
Akhtar, Othman Salim, Sheeba, Ba Aqeel, Azad, Farhan, Alessi, Lauren, Hansen, Doris, Alsina, Melissa, Baz, Rachid, Shain, Kenneth, Grajales Cruz, Ariel, Castaneda Puglianini, Omar, Liu, Hien, Blue, Brandon, Nishihori, Taiga, Al Jumayli, Mohammed, Extermann, Martine, Locke, Frederick L., Mhaskar, Rahul, and Freeman, Ciara Louise
- Abstract
Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CAR-T) therapy is transforming the care of patients with relapsed/refractory multiple myeloma (MM). Unfortunately, despite being a disease of older adults these patients remain under-represented in most pivotal clinical trials. We performed a systematic review and proportion meta-analysis of prospective clinical trials and observational studies of anti-BCMA CAR-T therapy in patients with MM with the aim to determine the efficacy and safety of this therapy in older adults (≥65 years). We searched the Pubmed, Scopus, Web of Science (WOS), Ovid, Embase, CENTRAL, and CINAHL databases through September 9, 2022 and abstracts from the American Society of Hematology (ASH) Annual Meeting 2022. Primary outcome measures included overall response rate (ORR), rates of cytokine release syndrome (CRS), and immune cell-effector-associated neurotoxicity syndrome (ICANS). study was registered with PROSPERO (study number: CRD42022334287). After screening 2218 references, 14 studies were included for data extraction, with a total of 558 patients, 26.2% (n = 146) of whom were older adults. The pooled ORR amongst this population was 93%, which was comparable to the ORR of 86% amongst younger patients. In older adults, the rates of CRS (any grade) and grade ≥ 3 were 95% and 21%, respectively. For younger patients, the pooled rate of CRS (any grade) and grade ≥ 3 CRS was 91% and 20%, respectively. The rate of ICANS (any grade) in older adults was 15%, which was higher than that observed in those <65 years. Older adults experience comparable outcomes to younger patients with anti-BCMA CAR-T therapy, albeit with numerically higher rates of neurotoxicity. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Autologous Stem Cell Transplantation in Central Nervous System Lymphoma: A Multicenter Retrospective Series and a Review of the Literature.
- Author
-
Dholaria, Bhagirathbhai R., Kumar, Ambuj, Azzuqua, Abdel-Ghani, Nishihori, Taiga, Kharfan-Dabaja, Mohamed A., Tun, Han W., and Ayala, Ernesto
- Published
- 2019
- Full Text
- View/download PDF
7. TP53 and IDH2 Somatic Mutations Are Associated With Inferior Overall Survival After Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome.
- Author
-
Kharfan-Dabaja, Mohamed A., Komrokji, Rami S., Zhang, Qing, Kumar, Ambuj, Tsalatsanis, Athanasios, Perkins, Janelle, Nishihori, Taiga, Field, Teresa, Al Ali, Najla, Mishra, Asmita, Sallman, David, Salem, Karma Z., Zhang, Ling, Moscinski, Lynn, Fernandez, Hugo F., Lancet, Jeffrey, List, Alan, Anasetti, Claudio, and Padron, Eric
- Published
- 2017
- Full Text
- View/download PDF
8. Integrating Genomics in Myelodysplastic Syndrome to Predict Outcomes After Allogeneic Hematopoietic Cell Transplantation.
- Author
-
Nassereddine, Samah, Nishihori, Taiga, Padron, Eric, Mahfouz, Rami, Bazarbachi, Ali, Komrokji, Rami S., and Kharfan-Dabaja, Mohamed A.
- Published
- 2017
- Full Text
- View/download PDF
9. Pretransplantation 5-Azacitidine in High-Risk Myelodysplastic Syndrome.
- Author
-
Nishihori, Taiga, Perkins, Janelle, Mishra, Asmita, Komrokji, Rami, Kim, Jongphil, Kharfan-Dabaja, Mohamed A., Perez, Lia, Lancet, Jeffrey, Fernandez, Hugo, List, Alan, Anasetti, Claudio, and Field, Teresa
- Subjects
- *
AZACITIDINE , *PREVENTIVE medicine , *MYELODYSPLASTIC syndromes treatment , *STEM cell transplantation , *ORGAN donation , *PHARMACOKINETICS , *DRUG administration , *THERAPEUTICS - Abstract
Abstract: We prospectively evaluated the allogeneic hematopoietic cell transplantation (HCT) outcomes in high-risk myelodysplastic syndrome (MDS) patients who received pretransplantation 5-azacitidine. Twenty-five patients evaluated for allogeneic HCT consult and considered medically eligible for a donor search were enrolled. Azacitidine was administered at 75 mg/m2 for 5 to 7 days every 4 weeks until a suitable donor was found. A median of 3 (range, 0 to 6) cycles of 5-azacitidine were administered. Preallogeneic HCT responses to 5-azacitidine, based on the International Working Group criteria, were 48% partial response, 33% stable disease, and 19% progressive disease. Four patients did not proceed to allogeneic HCT. Twenty-one patients, a median age of 55 (range, 25 to 67) years, received allogeneic HCT after myeloablative pharmacokinetically targeted i.v. busulfan and fludarabine conditioning regimen. Donors were either HLA-matched related or unrelated, except for 1 mismatch unrelated donor. With a median follow-up of 30 months, 1-year relapse-free and overall survivals were 52% (95% confidence interval [CI], 30% to 71%) and 62% (95% CI, 38% to 79%), respectively. Preallogeneic HCT 5-azacitidine administration was well tolerated and provided reasonable disease control before allogeneic HCT. (Registered at ClinicalTrials.gov as NCT00660400). [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
10. Monoclonal Antibodies in Conditioning Regimens for Hematopoietic Cell Transplantation.
- Author
-
Kharfan-Dabaja, Mohamed A., Nishihori, Taiga, Otrock, Zaher K., Haidar, Nour, Mohty, Mohamad, and Hamadani, Mehdi
- Subjects
- *
MONOCLONAL antibodies , *HEMATOPOIETIC stem cell transplantation , *AUTOTRANSPLANTATION , *RITUXIMAB , *B cells , *RANDOMIZED controlled trials , *RADIOIMMUNOTHERAPY - Abstract
Abstract: Monoclonal antibodies are increasingly being incorporated in conditioning regimens for autologous or allogeneic hematopoietic cell transplantation (HCT). The benefit of adding rituximab to autologous HCT regimens is purportedly related to in vivo purging of clonal B cells. Randomized trials comparing the addition (or not) of rituximab to high-dose therapy regimens are lacking. No benefit of standard-dose radioimmunotherapy-based regimens for autografting in aggressive lymphomas was seen in a randomized controlled study. The incorporation of rituximab into allogeneic HCT regimens aims to improve responses while reducing nonrelapse mortality resulting from acute graft-versus-host disease. The optimal dose and administration schedule of rituximab in this setting are unknown, and potentially serious complications from increased infections owing to prolonged (and profound) cytopenias or persistent hypogammaglobulinemia are of concern. Radioimmunotherapy-based conditioning for allografting holds promise as a modality to optimize tumor control and synergize adoptive immunotherapy effects, but it remains experimental at this time. The addition of alemtuzumab to allogeneic HCT regimens is associated with prolonged lymphopenia and impaired immune reconstitution, high relapse rates, and serious infections. The optimal dose and schedule of alemtuzumab to avoid prolonged immune paresis remain elusive. It is anticipated that additional monoclonal antibodies will soon become available that can be incorporated into HCT regimens after safety and clinical efficacy are demonstrated. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
11. Therapeutic Advances in the Treatment of Primary Plasma Cell Leukemia: A Focus on Hematopoietic Cell Transplantation.
- Author
-
Nishihori, Taiga, Abu Kar, Sarah M., Baz, Rachid, Alsina, Melissa, Harousseau, Jean-Luc, and Kharfan-Dabaja, Mohamed A.
- Subjects
- *
PLASMA cell leukemia , *HEMATOPOIETIC stem cell transplantation , *PLASMA cell diseases , *CYTOGENETICS , *DISEASES , *IMMUNOREGULATION , *PROGNOSIS - Abstract
Abstract: Primary plasma cell leukemia (pPCL) is an uncommon but aggressive plasma cell malignancy associated with frequent extramedullary involvement, high-risk cytogenetic abnormalities, and frequent organ dysfunction, ultimately resulting in poor prognosis. Here we review recent advances in our understanding of the molecular and biological aspects of PCL and summarize therapeutic progress occurring over the past 2 decades. pPCL is distinguished from secondary PCL arising from multiple myeloma. The molecular and immunophenotypic changes of pPCL are often distinct from those seen in secondary PCL and multiple myeloma. The availability of novel agents (ie, proteasome inhibitors and immunomodulatory agents) and the increasing use of hematopoietic cell transplantation strategies have resulted in better outcomes, although long-term survival remains poor. Development of complex treatment algorithms that combine novel agents as induction therapy, as part of conditioning regimens for hematopoietic cell transplantation (autologous or allogeneic), or as post-transplantation remission strategies are logical and may translate into improved survival in patients with PCL. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
12. Clinical Outcomes of Patients With Plasma Cell Leukemia in the Era of Novel Therapies and Hematopoietic Stem Cell Transplantation Strategies: A Single-Institution Experience.
- Author
-
Lebovic, Daniel, Ling Zhang, Alsina, Melissa, Nishihori, Taiga, Shain, Kenneth H., Sullivan, Daniel, Ochoa-Bayona, Jose L., Kharfan-Dabaja, Mohamed A., and Baz, Rachid
- Published
- 2011
- Full Text
- View/download PDF
13. Open-Label Pilot Study of Genetically Engineered NY-ESO-1 Specific T Cells (GSK3377794) Alone or in Combination with Pembrolizumab in Relapsed and Refractory Multiple Myeloma.
- Author
-
Nishihori, Taiga, Kaufman, Jonathan L., Hoffman, James E., Blouch, Kristin, Pandit, Sunil, Butler, Emily, Jain, Amit, Wu, Yuehui, DeYoung, M. Phillip, Hasan, Aisha N., Farsaci, Benedetto, Chisamore, Michael, and Rapoport, Aaron P.
- Subjects
- *
LEUKAPHERESIS , *MULTIPLE myeloma , *PEMBROLIZUMAB , *STEM cell transplantation , *PILOT projects , *BONE marrow - Abstract
NY-ESO-1 TCR T (GSK3377794) are autologous polyclonal T cells transduced by a self-inactivating lentiviral vector to express an affinity-enhanced TCR recognizing NY-ESO-1 or LAGE-1a antigenic peptides in complex with HLA-A2. NY-ESO-1 and LAGE-1a are immunogenic cancer/testis antigens overexpressed in mutiple myeloma (MM) and linked to poor clinical outcome. Patients (pts) with MM who received GSK3377794 after autologous stem cell transplant (ASCT) showed encouraging clinical activity. PD-1 expression on CD8 T cells can occur in GSK3377794-treated MM pts and may limit adaptive immune response; this is a mechanism of resistance/relapse in CD19 CAR T-cell trials. Combining GSK3377794 with an anti-PD1 inhibitor (pembrolizumab) may have synergistic antitumor activity. Evaluate safety and efficacy of GSK3377794 alone or in combination with pembrolizumab in pts with relapsed MM. This is an open-label, pilot study (NCT03168438) of GSK3377794 in pts who are HLA-A*02:01, 05, ± 06 positive and have NY-ESO-1+/LAGE-1a+ relapsed/refractory MM. Twenty pts who have received ≥3 prior therapies containing ≥1 (separately or combined; including ASCT) of an IMiD, PI, alkylator, CD38 monoclonal antibody, and glucocorticoid, will be assigned to 1 of 2 arms: GSK3377794 as a single infusion (Arm 1, n=10) or GSK3377794 as a single infusion + pembrolizumab 200 mg IV every 3 wk (Arm 2, n=10). Arm 1 enrollment will complete before enrolling Arm 2. Pembrolizumab treatment will start from Wk 3 (Wk 6 if precluded by toxicity). Each patient will undergo leukapheresis to obtain cells for autologous NY-ESO-1-specific T-cell manufacturing, followed by lymphodepleting chemotherapy with fludarabine + cyclophosphamide, then GSK3377794 infusion of 1−8 × 109 transduced T cells. Study objectives are to assess safety and tolerability (primary) and antitumor activity (secondary) of GSK3377794 treatment (± pembrolizumab). At each visit, pts will be monitored for AEs and treatment-limiting toxicities, efficacy (using IMWG criteria), and biomarkers. Arm 2 enrollment will pause for a 3-wk safety review period after the first 3 pts receive their first pembrolizumab dose. Treatment will continue until disease progression or 108 wk after GSK3377794 infusion. After completing treatment, pts will transfer to long-term follow-up (NCT03391778) to continue safety/survival monitoring for up to 15 years. As of Jan 27, 2019, 50 pts have been screened. Half have tested positive for HLA-A*02:01, 05, ± 06; bone marrow samples from 12/21 (57%) tested positive for NY-ESO-1 ± LAGE-1a. To date, 3 pts have received GSK3377794. Further work is ongoing to enhance patient eligibility. These data are presented on behalf of the original authors with their permission. A similar presentation will be presented at the ASH Annual Meeting, Orlando, FL, USA, Dec 7-10, 2019. This study (NCT03168438) is funded by GSK. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
14. 656 - A Year in the Life of an Agnis Data Submitting HSCT Center.
- Author
-
Hillgruber, Ryan, Nishihori, Taiga, Coyle, Diane, Feliciano, Noemi, Gibson, Christine, Ochoa, Tatiana, McCormick, Samantha, Rabelo, Sasha, and Mujezinovic, Edina
- Published
- 2018
- Full Text
- View/download PDF
15. Allogeneic Hematopoietic Cell Transplantation for Richter Syndrome: A Single-Center Experience.
- Author
-
Kharfan-Dabaja, Mohamed A., Kumar, Ambuj, Stingo, Facundo E., Khimani, Farhad, Hussaini, Mohammad, Ayala, Ernesto, Nishihori, Taiga, Shah, Bijal, Locke, Frederick L., Pinilla-Ibarz, Javier, and Chavez, Julio C.
- Published
- 2018
- Full Text
- View/download PDF
16. Bendamustine appears to be a safe and effective alternative to carmustine when combined with etoposide, cytarabine and melphalan as conditioning regimen for autologous HCT for lymphomas: results of a systematic review/meta-analysis.
- Author
-
Rafei, Hind, Reljic, Tea, Nishihori, Taiga, Ayala, Ernesto, Kumar, Ambuj, and Kharfan-Dabaja, Mohamed A.
- Published
- 2017
- Full Text
- View/download PDF
17. Allo-HCT regimens with low toxicity needed in older patients with acute myeloid leukaemia.
- Author
-
Kharfan-Dabaja, Mohamed A, Nishihori, Taiga, and Bazarbachi, Ali
- Subjects
- *
ACUTE myeloid leukemia , *ACUTE myeloid leukemia treatment , *DRUG toxicity , *DISEASES in older people , *CLINICAL trials , *PATIENTS - Published
- 2016
- Full Text
- View/download PDF
18. Allogeneic Hematopoietic Cell Transplantation Using Fludarabine, Melphalan and Bortezomib (Flu/Mel/Vel) Conditioning for Consolidation of VGPR or CR in Myeloma.
- Author
-
Nishihori, Taiga, Ochoa-Bayona, Jose Leonel, Sullivan, Daniel, Baz, Rachid, Shain, Kenneth, Hillgruber, Ryan, Anasetti, Claudio, and Alsina, Melissa
- Published
- 2014
- Full Text
- View/download PDF
19. Hepatobiliary manifestations of acute myeloid leukemia
- Author
-
Nishihori, Taiga, Fernandez, Hugo F., Coppola, Domenico, Ochoa-Bayona, Jose L., Lancet, Jeffrey E., Komrokji, Rami S., and Kharfan-Dabaja, Mohamed A.
- Published
- 2011
- Full Text
- View/download PDF
20. Extracorporeal Photopheresis in Steroid-Refractory Acute or Chronic Graft-versus-Host Disease: Results of a Systematic Review of Prospective Studies.
- Author
-
Abu-Dalle, Iman, Reljic, Tea, Nishihori, Taiga, Antar, Ahmad, Bazarbachi, Ali, Djulbegovic, Benjamin, Kumar, Ambuj, and Kharfan-Dabaja, Mohamed A.
- Subjects
- *
GRAFT versus host disease , *HEMATOPOIETIC stem cell transplantation , *IMMUNE system , *GASTROINTESTINAL system , *ADRENOCORTICAL hormones , *CHRONIC diseases - Abstract
Acute and chronic graft-versus-host disease (GVHD) remain major obstacles for successful allogeneic hematopoietic cell transplantation. Extracorporeal photopheresis (ECP) modulates immune cells, such as alloreactive T cells and dendritic cells, and improves GVHD target organ function(s) in steroid-refractory GVHD patients. We performed a systematic review to evaluate the totality of evidence regarding the efficacy of ECP for treatment of acute and chronic steroid-refractory or steroid-dependent GVHD. Nine studies, including 1 randomized controlled trial, met inclusion criteria, with a total of 323 subjects. In pooled analyses, overall response rates (ORR) were .69 (95% confidence interval [CI], .34 to .95) and .64 (95% CI, .47 to .79) for acute and chronic GVHD, respectively. In acute GVHD organ-specific responses, ECP resulted in the highest ORR for cutaneous, with .84 (95% CI, .75 to .92), followed by gastrointestinal with .65 (95% CI, .52 to .78). Similar response rates were seen in chronic GVHD involving the skin and gastrointestinal tract. Conversely, ORR for chronic GVHD involving the lungs was only .15 (95% CI, 0 to .5). In chronic GVHD, grades 3 to 4 adverse events were reported at .38 (95% CI, .06 to .78). ECP-related mortality rates were extremely low. Rates of immunosuppression discontinuation were .55 (95% CI, .40 to .70) and .23 (95% CI, .07 to .44) for acute and chronic GVHD, respectively. In summary, albeit limited by numbers of available studies, pooled analyses of prospective studies demonstrate encouraging responses after ECP treatment in acute and chronic GVHD after failing corticosteroids. Further research efforts are needed to improve organ-specific responses. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
21. Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas After Chimeric Antigen Receptor T-Cell Therapy.
- Author
-
Figura, Nicholas B., Robinson, Timothy J., Sim, Austin J., Wang, Xuefeng, Cao, Biwei, Chavez, Julio C., Shah, Bijal D., Khimani, Farhad, Lazaryan, Aleksandr, Davila, Marco, Bachmeier, Christina, Nishihori, Taiga, Liu, Hien D., Kim, Sungjune, Locke, Frederick L., and Jain, Michael D.
- Subjects
- *
CHIMERIC antigen receptors , *T cells , *AUTOMOBILES , *OVERALL survival , *ANTIGEN receptors - Abstract
Purpose: Chimeric antigen receptor T-cell (CAR T) therapy is capable of eliciting durable responses in patients with relapsed/refractory (R/R) lymphomas. However, most treated patients relapse. Patterns of failure after CAR T have not been previously characterized, and may provide insights into the mechanisms of resistance guiding future treatment strategies.Methods and Materials: This is a retrospective analysis of patients with R/R large B-cell lymphoma who were treated with anti-CD19 CAR T at a National Cancer Institute-designated Comprehensive Cancer Center between 2015 and 2019. Pre- and posttreatment positron emission/computed tomography scans were analyzed to assess the progression of existing (local failures) versus new, nonoverlapping lesions (de novo failures) and identify lesions at a high risk for progression.Results: A total of 469 pretreatment lesions in 63 patients were identified. At a median follow-up of 12.6 months, 36 patients (57%) recurred. Most (n = 31; 86%) had a component of local failure, and 13 patients (36%) exhibited strictly local failures. Even when progressing, 84% of recurrent patients continued to have a subset of pretreatment lesions maintain positron emission/computed tomography resolution. Lesions at a high risk for local failure included those with a diameter ≥5 cm (odds ratio [OR], 2.34; 95% confidence interval [CI], 1.55-3.55; P < .001), maximum standardized uptake value ≥10 (OR, 2.08; 95% CI, 1.38-3.12; P < .001), or those that were extranodal (OR, 1.49; 95% CI, 1.10-2.04; P = .01). In the 69 patients eligible for survival analysis, those with any lesion ≥5 cm (n = 46; 67%) experienced inferior progression-free survival (hazard ratio, 2.41; 95% CI, 1.15-5.04; P = .02) and overall survival (hazard ratio, 3.36; 95% CI, 1.17-9.96; P = .02).Conclusions: Most patients who recur after CAR T experience a component of local progression. Furthermore, lesions with high-risk features, particularly large size, were associated with inferior treatment efficacy and patient survival. Taken together, these observations suggest that lesion-specific resistance may contribute to CAR T treatment failure. Locally directed therapies to high-risk lesions, such as radiation therapy, may be a viable strategy to prevent CAR T failures in select patients. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
22. Diagnostic and Therapeutic Advances in Blastic Plasmacytoid Dendritic Cell Neoplasm: A Focus on Hematopoietic Cell Transplantation.
- Author
-
Kharfan-Dabaja, Mohamed A., Lazarus, Hillard M., Nishihori, Taiga, Mahfouz, Rami A., and Hamadani, Mehdi
- Subjects
- *
PLASMACYTOMA , *DENDRITIC cells , *CANCER invasiveness , *MYELOID leukemia , *GENE expression , *BIOMARKERS - Abstract
Abstract: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an exceedingly rare disorder categorized under acute myeloid leukemia by the World Health Organization. Phenotypically, malignant cells coexpress CD4+ and CD56+ without coexpressing common lymphoid or myeloid lineage markers. BPDCN frequently expresses CD123, TCL1, BDCA-2, and CD2AP. Restriction of CD2AP expression to plasmacytoid dendritic cells makes it a useful tool to help confirm diagnosis. Clonal complex chromosome aberrations are described in two-thirds of cases. Eighty percent of BPDCN cases present with nonspecific dermatological manifestations, prompting inclusion in the differential diagnosis of atypical skin rashes refractory to standard treatment. Prognosis is poor, with a median survival of less than 18 months. No prospective randomized data exist to define the most optimal frontline chemotherapy. Current practice considers acute myeloid leukemia-like or acute lymphoblastic leukemia–like regimens acceptable for induction treatment. Unfortunately, responses are short-lived, with second remissions difficult to achieve, underscoring the need to consider hematopoietic cell transplantation early in the disease course. Allografting, especially if offered in first remission, can result in long-term remissions. Preclinical data suggest a potential role for immunomodulatory agents in BPCDN. However, further research efforts are needed to better understand BPDCN biology and to establish evidence-based treatment algorithms that might ultimately improve overall prognosis of this disease. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
23. ATG Prevents Severe Acute Graft-versus-Host Disease in Mismatched Unrelated Donor Hematopoietic Cell Transplantation
- Author
-
Pidala, Joseph, Tomblyn, Marcie, Nishihori, Taiga, Ayala, Ernesto, Field, Teresa, Fernandez, Hugo, Perez, Lia, Locke, Fred, Alsina, Melissa, Ochoa, Jose Leonel, Perkins, Janelle, Tate, Cheryl, Shapiro, Jamie, Conwell, Michelle, Bookout, Ryan, and Anasetti, Claudio
- Subjects
- *
GRAFT versus host disease , *STEM cell transplantation , *HEMATOPOIETIC stem cells , *MORTALITY , *RETROSPECTIVE studies , *METHOTREXATE , *CYTOMEGALOVIRUS diseases , *LYMPHOPROLIFERATIVE disorders , *DIAGNOSIS - Abstract
Severe acute graft-versus-host disease (aGVHD) remains a major source of morbidity and mortality following mismatched unrelated donor hematopoietic cell transplantation (HCT). Through a retrospective analysis, we investigated the efficacy of GVHD prophylaxis with rabbit anti-thymocyte globulin (ATG) 7.5 mg/kg (1 mg/kg given on day −3, then 3.25 mg/kg/day on days −2 and −1 before stem cell infusion) followed by standard tacrolimus plus methotrexate in a consecutive series of 45 HLA partially matched unrelated donor HCT recipients. The cumulative incidence of grade III-IV aGVHD was 11% by 100 days (95% confidence interval [CI] 5%-25%). Moderate to severe chronic GVHD (per NIH consensus criteria) was 19% (95% CI 10%-36%) at 1 year, and 28% (95% CI 16%-48%) at 2 years. With a median follow-up time for surviving patients of 12 months (range: 5-39 months), overall survival was 55% (95% CI 39%-71%) at 1 year, and 45% (95% CI 27%-63%) at 2 years. Nonrelapse mortality was 11% (95% CI 5%-25%) by 100 days post-HCT, 26% (95% CI 16%-44%) by 1 year, and 30% (95% CI 18%-50%) by 2 years. The cumulative incidence of primary disease relapse was 23% (95% CI 13%-41%) at 1 year, and 33% (95% CI 20%-56%) by 2 years after HCT. Cytomegalovirus (CMV) infection or reactivation varied according to recipient and donor CMV serostatus. Epstein-Barr Virus (EBV) reactivation occurred in 54% (95% CI 40%-71%) of patients. Preemptive rituximab therapy was administered for EBV reactivation, however, posttransplant lymphoproliferative disorder was diagnosed in 5 (11%) cases, and was fatal in 1. A regimen of ATG 7.5 mg/kg total ending on day −1 effectively decreased the occurrence of grade III-IV aGVHD and severe chronic GVHD. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
24. Sole Upfront Therapy with Beclomethasone and Budesonide for Upper Gastrointestinal Acute Graft-versus-Host Disease.
- Author
-
Frairia, Chiara, Nicolosi, Maura, Shapiro, Jamie, Kim, Jongphil, Betts, Brian C., Fernandez, Hugo F., Locke, Frederick L., Mishra, Asmita, Nishihori, Taiga, Ochoa-Bayona, Jose Leonel, Perez, Lia, Pidala, Joseph, and Anasetti, Claudio
- Subjects
- *
BUSULFAN , *GRAFT versus host disease , *GLUCOCORTICOIDS , *ACUTE diseases , *BUDESONIDE , *BECLOMETHASONE dipropionate , *HEMATOPOIETIC stem cell transplantation - Abstract
• Upper gastro-intestinal acute GVHD may improve with sole upfront topical steroids. • Combined beclomethasone and budesonide are safe in upper gastro-intestinal GVHD. • Prospective trials should explore the advantages of topical over systemic steroids. Systemic glucocorticoids remain the standard treatment for gastrointestinal (GI) acute graft-versus-host disease (aGVHD) despite their toxicity and incomplete efficacy. Controlled trials have tested poorly absorbable steroids as adjuncts with systemic glucocorticoids, but only small case series have reported treatment with poorly absorbed beclomethasone dipropionate (BDP) and budesonide (BUD) alone. Our team has adopted the practice of administering BDP or BDP+BUD without systemic glucocorticoids as first-line therapy for isolated upper GI (UGI) aGVHD. We report results in 76 patients treated with BDP alone and in 81 patients treated with BDP+BUD, with allocation by physician choice. Almost all patients received peripheral blood stem cells (92%) from a fully HLA-matched related or unrelated donor (80%) after myeloablative conditioning (76%) for acute leukemia (49%), myelodysplastic syndrome (17%), non-Hodgkin lymphoma (14%), or another hematopoietic disorders (20%). After 28 days of treatment with BDP, 46% of the patients had a complete response (CR) and 10% had a partial response (PR); after 200 days, 61 (80%) patients were alive, 34% maintained a CR, and 3% maintained a PR, whereas 53% required additional immunosuppression (IS). After 28 days of treatment with BDP+BUD, 67% had a CR and 10% a PR; after 200 days, 74 (91%) patients were alive, 46% maintained a CR, and 2% maintained a PR, whereas 43% required additional IS. Among the entire cohort of 157 patients, 66 (42%) were treated successfully without systemic glucocorticoids. This study reports the efficacy of poorly absorbable steroids alone for patients with isolated UGI aGVHD. Prospective trials should test for the potential advantages of BDP and BUD use over systemic glucocorticoids. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
25. 115 - Moffitt's ICE-T Fuels CAR-T Infrastructure Execution for Commercial Launch.
- Author
-
Repaczki-Jones, Ramona, Locke, Frederick L., Nishihori, Taiga, Anasetti, Claudio, and Eldredge, Scott
- Published
- 2018
- Full Text
- View/download PDF
26. Allogeneic hematopoietic cell transplantation in T-cell prolymphocytic leukemia: A single-center experience.
- Author
-
Dholaria, Bhagirathbhai R., Ayala, Ernesto, Sokol, Lubomir, Nishihori, Taiga, Chavez, Julio C., Hussaini, Mohammad, Kumar, Ambuj, and Kharfan-Dabaja, Mohamed A.
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *LEUKEMIA treatment , *ALEMTUZUMAB , *DISEASE remission , *RAPAMYCIN , *THERAPEUTICS - Abstract
Background T- cell prolymphocytic leukemia (T- PLL) is a rare aggressive hematological malignancy. Alemtuzumab, an anti-CD52 humanized monoclonal antibody, is the treatment of choice for remission induction. Allogeneic hematopoietic cell transplantation (allo-HCT) has been described to induce durable remissions and improve survival, but data is limited. Patients and methods We evaluated clinical outcomes of 11 patients, median age of 56 (range, 43–71) years who underwent allo-HCT for T-PLL. The majority of cases were in the first complete remission (CR1 = 9, CR2 = 1, second partial response PR2 = 1) at time of allo-HCT. Myeloablative conditioning was the most commonly prescribed preparative regimen (n = 8, 73%) and tacrolimus plus sirolimus was most commonly prescribed regimen for graft-versus-host disease prophylaxis (n = 5, 46%). Results The median follow-up for surviving patients was 48 (range, 6–123) months. The 4-year progression-free survival (PFS) and overall survival (OS) were 45% (95% confidence interval (CI) = 13–78%) and 56% (95% CI = 24–89%), respectively. Cumulative incidence of non-relapse mortality (NRM) at 4-year post-transplantation was 34% (95%CI = 14–85%). The 4-year cumulative incidence of relapse/progression was 21% (95% CI = 6–71%). Conclusion Allo-HCT is an effective treatment for T-PLL. Patients must be evaluated for their candidacy for allo-HCT as soon as the diagnosis is confirmed. Efforts are needed to decrease NRM and relapse. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
27. Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival.
- Author
-
Htut, Myo, D'Souza, Anita, Krishnan, Amrita, Bruno, Benedetto, Zhang, Mei-Jie, Fei, Mingwei, Diaz, Miguel Angel, Copelan, Edward, Ganguly, Siddhartha, Hamadani, Mehdi, Kharfan-Dabaja, Mohamed, Lazarus, Hillard, Lee, Cindy, Meehan, Kenneth, Nishihori, Taiga, Saad, Ayman, Seo, Sachiko, Ramanathan, Muthalagu, Usmani, Saad Z., and Gasparetto, Christina
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *MULTIPLE myeloma treatment , *CANCER immunotherapy , *MONOCLONAL antibodies , *SURVIVAL analysis (Biometry) , *FOLLOW-up studies (Medicine) - Abstract
We compared postrelapse overall survival (OS) after autologous/allogeneic (auto/allo) versus tandem autologous (auto/auto) hematopoietic cell transplantation (HCT) in patients with multiple myeloma (MM). Postrelapse survival of patients receiving an auto/auto or auto/allo HCT for MM and prospectively reported to the Center for International Blood and Marrow Transplant Research between 2000 and 2010 were analyzed. Relapse occurred in 404 patients (72.4%) in the auto/auto group and in 178 patients (67.4%) in the auto/allo group after a median follow-up of 8.5 years. Relapse occurred before 6 months after a second HCT in 46% of the auto/allo patients, compared with 26% of the auto/auto patients. The 6-year postrelapse survival was better in the auto/allo group compared with the auto/auto group (44% versus 35%; P = .05). Mortality due to MM was 69% (n = 101) in the auto/allo group and 83% (n = 229) deaths in auto/auto group. In multivariate analysis, both cohorts had a similar risk of death in the first year after relapse (hazard ratio [HR], .72; P = .12); however, for time points beyond 12 months after relapse, overall survival was superior in the auto/allo cohort (HR for death in auto/auto =1.55; P = .005). Other factors associated with superior survival were enrollment in a clinical trial for HCT, male sex, and use of novel agents at induction before HCT. Our findings shown superior survival afterrelapse in auto/allo HCT recipients compared with auto/auto HCT recipients. This likely reflects a better response to salvage therapy, such as immunomodulatory drugs, potentiated by a donor-derived immunologic milieu. Further augmentation of the post-allo-HCT immune system with new immunotherapies, such as monoclonal antibodies, checkpoint inhibitors, and others, merit investigation. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
28. Assessment of Impact of HLA Type on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia.
- Author
-
Hill, Brian T., Ahn, Kwang Woo, Hu, Zhen-Huan, Aljurf, Mahmoud, Beitinjaneh, Amer, Cahn, Jean-Yves, Cerny, Jan, Kharfan-Dabaja, Mohamed A., Ganguly, Siddhartha, Ghosh, Nilanjan, Grunwald, Michael R., Inamoto, Yoshihiro, Kindwall-Keller, Tamila, Nishihori, Taiga, Olsson, Richard F., Saad, Ayman, Seftel, Matthew, Seo, Sachiko, Szer, Jeffrey, and Tallman, Martin
- Subjects
- *
HLA histocompatibility antigens , *HEMATOPOIETIC stem cell transplantation , *CHRONIC lymphocytic leukemia , *DELETION mutation , *HOMOGRAFTS - Abstract
Chronic lymphocytic leukemia (CLL) is a common hematologic malignancy with many highly effective therapies. Chemorefractory disease, often characterized by deletion of chromosome 17p, has historically been associated with very poor outcomes, leading to the application of allogeneic hematopoietic stem cell transplantation (allo-HCT) for medically fit patients. Although the use of allo-HCT has declined since the introduction of novel targeted therapy for the treatment of CLL, there remains significant interest in understanding factors that may influence the efficacy of allo-HCT, the only known curative treatment for CLL. The potential benefit of transplantation is most likely due to the presence of alloreactive donor T cells that mediate the graft-versus-leukemia (GVL) effect. The recognition of potentially tumor-specific antigens in the context of class I and II major histocompatibility complex on malignant B lymphocytes by donor T cells may be influenced by subtle differences in the highly polymorphic HLA locus. Given previous reports of specific HLA alleles impacting the incidence of CLL and the clinical outcomes of allo-HCT for CLL, we sought to study the overall survival and progression-free survival of a large cohort of patients with CLL who underwent allo-HCT from fully HLA-matched related and unrelated donors at Center for International Blood and Marrow Transplant Research transplantation centers. We found no statistically significant association of allo-HCT outcomes in CLL based on previously reported HLA combinations. Additional study is needed to further define the immunologic features that portend a more favorable GVL effect after allo-HCT for CLL. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
29. Hypoalbuminemia at Day +90 Is Associated with Inferior Nonrelapse Mortality and Overall Survival in Allogeneic Hematopoietic Cell Transplantation Recipients: A Confirmatory Study.
- Author
-
Murthy, Hemant S., Sheets, Kyle, Kumar, Ambuj, Nishihori, Taiga, Mina, Alain, Chavez, Julio C., Ayala, Ernesto, Field, Teresa, Mathews, John, Locke, Frederick, Perez, Lia, Betts, Brian C., Khimani, Farhad, Miladinovic, Branco, Tsalatsanis, Athanasios, Ochoa-Bayona, Jose Leonel, Alsina, Melissa, Fernandez, Hugo, Pidala, Joseph, and Anasetti, Claudio
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *ACUTE myeloid leukemia treatment , *BONE marrow transplant complications , *BIOMARKERS , *BLOOD serum analysis , *DISEASE relapse - Abstract
Prognostic biomarkers in allogeneic hematopoietic cell transplantation (allo-HCT) are needed to improve risk assessment and help guide therapeutic and surveillance strategies to mitigate the risk of death from the procedure. We previously identified hypoalbuminemia at day +90 post-transplantation as an independent predictor of increased nonrelapse mortality (NRM) and inferior overall survival (OS) in patients with acute myelogenous leukemia and myelodysplastic syndrome who were treated with an allo-HCT. Here, we aim to confirm the prognostic significance of day +90 hypoalbuminemia in 783 patients, median age 52 years (range, 18 to 76), who received an allo-HCT for various hematologic malignancies and bone marrow failure syndromes. Multivariate analysis for NRM demonstrated a negative effect of low serum albumin levels (<3.0 versus 3.0 to 3.5 versus >3.5 g/dL) at day +90 post-transplantation (hazard ratios, 8.03 [95% CI, 3.59 to 17.97] versus 2.84 [95% CI, 1.59 to 5.08] versus reference; P < .0001). This was also the case for OS (hazard ratios, 6.86 [95% CI, 4.24 to 11.10] versus 1.52 [95% CI, 1.05 to 2.20] versus reference; P < .0001). Patients with hypoalbuminemia at day +90 post-transplantation are more likely to die from causes other than relapse, particularly infections. This large study confirms the ability of day +90 serum hypoalbuminemia to predict worse NRM and inferior OS. Presence of hypoalbuminemia at day +90 should drive a more rigorous real-time surveillance strategy considering the anticipated high-risk of NRM and poor survival in these patients. Future studies should consider incorporating day +90 serum albumin levels in prognostic models of NRM and OS. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
30. Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia.
- Author
-
Liu, Hien Duong, Ahn, Kwang Woo, Hu, Zhen-Huan, Hamadani, Mehdi, Nishihori, Taiga, Wirk, Baldeep, Beitinjaneh, Amer, Rizzieri, David, Grunwald, Michael R., Sabloff, Mitchell, Olsson, Richard F., Bajel, Ashish, Bredeson, Christopher, Daly, Andrew, Inamoto, Yoshihiro, Majhail, Navneet, Saad, Ayman, Gupta, Vikas, Gerds, Aaron, and Malone, Adriana
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *LEUKEMIA , *MORTALITY , *BONE marrow , *KARNOFSKY Performance Status - Abstract
Allogeneic hematopoietic cell transplantation (HCT) is potentially curative for patients with chronic myelomonocytic leukemia (CMML); however, few data exist regarding prognostic factors and transplantation outcomes. We performed this retrospective study to identify prognostic factors for post-transplantation outcomes. The CMML-specific prognostic scoring system (CPSS) has been validated in subjects receiving nontransplantation therapy and was included in our study. From 2001 to 2012, 209 adult subjects who received HCT for CMML were reported to the Center for International Blood and Marrow Transplant Research. The median age at transplantation was 57 years (range, 23 to 74). Median follow-up was 51 months (range, 3 to 122). On multivariate analyses, CPSS scores, Karnofsky performance status (KPS), and graft source were significant predictors of survival ( P = .004, P = .01, P = .01, respectively). Higher CPSS scores were not associated with disease-free survival, relapse, or transplantation-related mortality. In a restricted analysis of subjects with relapse after HCT, those with intermediate-2/high risk had a nearly 2-fold increased risk of death after relapse compared to those with low/intermediate-1 CPSS scores. Respective 1-year, 3-year, and 5-year survival rates for low/intermediate-1 risk subjects were 61% (95% confidence interval [CI], 52% to 72%), 48% (95% CI, 37% to 59%), and 44% (95% CI, 33% to 55%), and for intermediate-2/high risk subjects were 38% (95% CI, 28% to 49%), 32% (95% CI, 21% to 42%), and 19% (95% CI, 8% to 29%). We conclude that higher CPSS score at time of transplantation, lower KPS, and a bone marrow graft are associated with inferior survival after HCT. Further investigation of CMML disease–related biology may provide insights into other risk factors predictive of post-transplantation outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
31. Nonfluorodeoxyglucose-Avid Persistent Splenomegaly at Time of Transplantation Delays Neutrophil and Platelets Engraftment without Affecting Survival in Patients with Lymphomas Undergoing Allogeneic Hematopoietic Cell Transplantation.
- Author
-
Khimani, Farhad, Jeong, Daniel K., Miladinovic, Branko, Nishihori, Taiga, Ayala, Ernesto, Locke, Frederick, Mishra, Asmita, Chavez, Julio, Shah, Bijal, Gage, Kenneth, and Kharfan-Dabaja, Mohamed A.
- Subjects
- *
LYMPHOMA treatment , *HEMATOPOIETIC stem cell transplantation , *FLUORODEOXYGLUCOSE F18 , *NEUTROPHILS , *BLOOD platelets - Abstract
It is unclear if persistent splenomegaly in the presence of a negative positron emission tomography (PET) scan before allogeneic hematopoietic cell transplantation (HCT) influences post-transplantation outcomes in patients with lymphoma. We retrospectively reviewed records of 152 patients who underwent allogeneic HCT for various lymphomas. Centralized review of pretransplantation computed tomography (CT) and PET images was performed. Spleen volume (SV) was measured using the freehand volume segmentation tool in AW Workstation software (General Electric, Waukesha, WI). Splenic index (SI) was calculated as a product of width, thickness, and length of the spleen. Normal SV was defined as SV < 314.5 cm 3 and normal SI was defined as SI ≤ 480 cm 3 , as described in the literature. Among the study population, 42.8% received an allogeneic HCT from an HLA-matched related donor, 36.2% from a matched unrelated donor, 12.5% from a mismatched unrelated donor, and 8.6% received a double umbilical cord blood transplantation. Most (61.8%) received myeloablative conditioning. Median age at transplantation was 52 (range, 21 to 68) years. Pre–allogeneic HCT spleen CT and PET images were available on 88% and 70.3% patients, respectively. SV ranged from 90 cm 3 to 4684 cm 3 with a median of 290.5 cm 3 and a mean of 400.3 cm 3 . SI calculation showed a range from 50.3 cm 3 to 8276.4 cm 3 with a median of 582.1 cm 3 and a mean of 771.2 cm 3 . The majority of patients (83.1%) had PET-negative spleen before allogeneic transplantation. Engraftment was delayed in PET-negative patients with persistent splenomegaly, with median days to neutrophil engraftment of 17 versus 16 ( P = .03) and median days to platelet engraftment of 16 versus 14 ( P = .04) when using SV. However, persistent splenomegaly did not appear to impact progression-free survival ( P = .11) or overall survival ( P = .37). Splenomegaly in the setting of a PET-negative study before allogeneic HCT delays neutrophil and platelet engraftment but does not appear to affect survival. Future studies using registry data or larger multicenter studies would be required to evaluate the impact of splenomegaly and its fluorodeoxyglucose avidity on allogeneic HCT outcomes in specific subtypes of lymphomas. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
32. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis.
- Author
-
Chaudhury, Sonali, Sparapani, Rodney, Hu, Zhen-Huan, Nishihori, Taiga, Abdel-Azim, Hisham, Malone, Adriana, Olsson, Richard, Hamadani, Mehdi, Daly, Andrew, Bacher, Ulrike, Wirk, Baldeep M., Kamble, Rammurti T., Gale, Robert P., Wood, William A., Hale, Gregory, Wiernik, Peter H., Hashmi, Shahrukh K., Marks, David, Ustun, Celalettin, and Munker, Reinhold
- Subjects
- *
TREATMENT of chronic myeloid leukemia , *CHILD patients , *HEMATOPOIETIC stem cell transplantation , *PROTEIN-tyrosine kinase inhibitors , *GRAFT versus host disease , *STEM cell donors , *GENETICS - Abstract
Chronic myeloid leukemia (CML) in children and young adults is uncommon. Young patients have long life expectancies and low morbidity with hematopoietic cell transplantation (HCT). Prolonged tyrosine kinase inhibitor (TKI) use may cause significant morbidity. In addition, indication for HCT in patients in the first chronic phase is not established. We hence retrospectively evaluated outcomes in 449 CML patients with early disease receiving myeloablative HCT reported to the CIBMTR. We analyzed various factors affecting outcome, specifically the effect of age and pre-HCT TKI in pediatric patients (age < 18 years, n = 177) and young adults (age 18 to 29 years, n = 272) with the goal of identifying prognostic factors. Post-HCT probability rates of 5-year overall survival (OS) and leukemia-free survival (LFS) were 75% and 59%, respectively. Rates of OS and LFS were 76% and 57% in <18-year and 74% and 60% in 18- to 29-year group, respectively, by univariate analysis ( P = .1 and = .6). Five-year rates of OS for HLA matched sibling donor (MSD) and bone marrow (BM) stem cell source were 83% and 80%, respectively. In multivariate analysis there was no effect of age (<18 versus 18 to 29) or pre-HCT TKI therapy on OS, LFS, transplant related mortality, or relapse. Favorable factors for OS were MSD ( P < .001) and recent HCT (2003 to 2010; P = .04). LFS was superior with MSD ( P < .001), BM as graft source ( P = .001), and performance scores > 90 ( P = .03) compared with unrelated or mismatched peripheral blood stem cells donors and recipients with lower performance scores. Older age was associated with increased incidence of chronic graft-versus-host disease ( P = .0002). In the current era, HCT outcomes are similar in young patients and children with early CML, and best outcomes are achieved with BM grafts and MSD. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
33. Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Peripheral T Cell Lymphomas as Front-Line Consolidation or in the Relapsed/Refractory Setting: A Systematic Review/Meta-Analysis.
- Author
-
El-Asmar, Jessica, Reljic, Tea, Ayala, Ernesto, Hamadani, Mehdi, Nishihori, Taiga, Kumar, Ambuj, and Kharfan-Dabaja, Mohamed A.
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *AUTOTRANSPLANTATION , *DRUG dosage , *T cells , *LYMPHOMA treatment , *SYSTEMATIC reviews , *CANCER - Abstract
To date, no prospective randomized trials exist comparing high-dose therapy (HDT) followed by autologous hematopoietic cell transplantation (auto-HCT) against conventional therapy for management of peripheral T cell lymphomas either as upfront consolidation or in the relapsed/refractory setting. Available data supporting this approach are limited to single-arm prospective or retrospective studies only. Accordingly, we performed a systematic review/meta-analysis of the published literature. Our search identified 1586 publications, but only 27 (n = 1368) met our inclusion criteria. In the front-line setting, pooled analysis of only prospective studies showed rates of progression-free survival (PFS) of 33% (95% confidence interval [CI], 14% to 56%), overall survival (OS) of 54% (95% CI, 32% to 75%), relapse/progression of 26% (95% CI, 20% to 33%), and transplantation-related mortality (TRM) of 2% (95% CI, 0% to 5%); for retrospective studies, rates of PFS, OS, relapse/progression, TRM, and secondary malignancies were 55% (95% CI, 40% to 69%), 68% (95% CI, 56% to 78%), 36% (95% CI, 24% to 48%), 6% (95% CI, 2% to 11%), and 7% (95% CI, 2% to 14%), respectively. On the other hand, pooled analysis of retrospective studies evaluating HDT/auto-HCT in the relapsed/refractory setting showed pooled rates of PFS, OS, relapse/progression, and TRM of 36% (95% CI, 32% to 40%), 47% (95% CI, 43% to 51%), 51% (95% CI, 39% to 62%), and 10% (95% CI, 5% to 17%), respectively. Among the various histologic subtypes, PFS and OS rates appear to be higher in anaplastic large cell lymphoma, regardless of disease stage. In the absence of a multicenter, randomized controlled trial comparing HDT/auto-HCT to a nontransplantation strategy, the findings of this systematic review/meta-analysis may represent the best evidence supporting the role of HDT/auto-HCT for treatment of peripheral T cell lymphomas as front-line consolidation or in the relapsed/refractory setting. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
34. Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies.
- Author
-
Pasquini, Marcelo C., Zhang, Mei-Jie, Medeiros, Bruno C., Armand, Philippe, Hu, Zhen-Huan, Nishihori, Taiga, Aljurf, Mahmoud D., Akpek, Görgün, Cahn, Jean-Yves, Cairo, Mitchell S., Cerny, Jan, Copelan, Edward A., Deol, Abhinav, Freytes, César O., Gale, Robert Peter, Ganguly, Siddhartha, George, Biju, Gupta, Vikas, Hale, Gregory A., and Kamble, Rammurti T.
- Subjects
- *
CELL transplantation , *CELLULAR therapy , *TRANSPLANTATION of organs, tissues, etc. , *STEM cell transplantation , *NEURAL stem cell transplantation - Abstract
The presence of monosomal karyotype (MK+) in acute myeloid leukemia (AML) is associated with dismal outcomes. We evaluated the impact of MK+ in AML (MK+AML, n = 240) and in myelodysplastic syndrome (MDS) (MK+MDS, n = 221) on hematopoietic cell transplantation outcomes compared with other cytogenetically defined groups (AML, n = 3360; MDS, n = 1373) as reported to the Center for International Blood and Marrow Transplant Research from 1998 to 2011. MK+ AML was associated with higher disease relapse (hazard ratio, 1.98; P < .01), similar transplantation-related mortality (TRM) (hazard ratio, 1.01; P = .90), and worse survival (hazard ratio, 1.67; P < .01) compared with those outcomes for other cytogenetically defined AML. Among patients with MDS, MK+ MDS was associated with higher disease relapse (hazard ratio, 2.39; P < .01), higher TRM (hazard ratio, 1.80; P < .01), and worse survival (HR, 2.02; P < .01). Subset analyses comparing chromosome 7 abnormalities (del7/7q) with or without MK+ demonstrated higher mortality for MK+ disease in for both AML (hazard ratio, 1.72; P < .01) and MDS (hazard ratio, 1.79; P < .01). The strong negative impact of MK+ in myeloid malignancies was observed in all age groups and using either myeloablative or reduced-intensity conditioning regimens. Alternative approaches to mitigate disease relapse in this population are needed. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
35. Impact of Pretransplantation 18F-fluorodeoxy Glucose–Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma.
- Author
-
Bachanova, Veronika, Burns, Linda J., Ahn, Kwang Woo, Laport, Ginna G., Akpek, Görgün, Kharfan-Dabaja, Mohamed A., Nishihori, Taiga, Agura, Edward, Armand, Philippe, Jaglowski, Samantha M., Cairo, Mitchell S., Cashen, Amanda F., Cohen, Jonathon B., D'Souza, Anita, Freytes, César O., Gale, Robert Peter, Ganguly, Siddhartha, Ghosh, Nilanjan, Holmberg, Leona A., and Inwards, David J.
- Subjects
- *
FLUORODEOXYGLUCOSE F18 , *GLUCOSE analysis , *POSITRON emission tomography , *HEALTH outcome assessment , *HEMATOPOIETIC stem cell transplantation , *HODGKIN'S disease - Abstract
Assessment with 18 F-fluorodeoxy glucose (FDG)–positron emission tomography (PET) before hematopoietic cell transplantation (HCT) for lymphoma may be prognostic for outcomes. Patients with chemotherapy-sensitive non–Hodgkin lymphoma (NHL) undergoing allogeneic HCT reported to the Center of International Blood and Marrow Transplantation Registry between 2007 and 2012 were included. Pre-HCT PET status (positive versus negative) was determined by the reporting transplantation centers. We analyzed 336 patients; median age was 55 years and 60% were males. Follicular lymphoma (n = 104) was more common than large cell (n = 85), mantle cell (n = 69), and mature natural killer or T cell lymphoma (n = 78); two thirds of the cohort received reduced-intensity conditioning; one half had unrelated donor grafts. Patients underwent PET scanning a median of 1 month (range, .07 to 2.83 months) before HCT; 159 were PET positive and 177 were PET negative. At 3 years, relapse/progression, progression-free survival (PFS), and overall survival (OS) in PET-positive versus PET-negative groups were 40% versus 26%; P = .007; 43% versus 47%; P = .47; and 58% versus 60%; P = .73, respectively. On multivariate analysis, a positive pretransplantation PET was associated with an increased risk of relapse/progression (risk ratio [RR], 1.86; P = .001) but was not associated with increased mortality (RR, 1.29, 95% confidence interval [CI], .96 to 1.7; P = .08), therapy failure (RR, 1.32; 95% CI, .95 to 1.84; P = .10), or nonrelapse mortality (RR, .75; 95% CI, .48 to 1.18; P = .22). PET status conferred no influence on graft-versus-host disease. A positive PET scan before HCT is associated with increased relapse risk but should not be interpreted as a barrier to a successful allograft. PET status does not appear to predict survival after allogeneic HCT for NHL. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
36. Ofatumumab in Combination with Glucocorticoids for Primary Therapy of Chronic Graft-versus-Host Disease: Phase I Trial Results.
- Author
-
Pidala, Joseph, Kim, Jongphil, Betts, Brian C., Alsina, Melissa, Ayala, Ernesto, Fernandez, Hugo F., Field, Teresa, Kharfan-Dabaja, Mohamed A., Locke, Frederick L., Mishra, Asmita, Nishihori, Taiga, Ochoa-Bayona, Leonel, Perez, Lia, Riches, Marcie, and Anasetti, Claudio
- Subjects
- *
GLUCOCORTICOIDS , *GRAFT versus host disease , *ADRENOCORTICAL hormones , *ANTI-inflammatory agents , *HYDROCORTISONE - Abstract
Standard primary therapy for chronic graft-versus-host disease (GVHD) is incompletely effective. Based on biologic insights implicating pathogenic B cells, we conducted a phase I trial examining the combination of standard (1 mg/kg/day prednisone) glucocorticoid therapy with ofatumumab, a humanized anti-CD20 monoclonal antibody, for primary chronic GVHD therapy. Patients ages ≥ 18 with National Institutes of Health Consensus moderate-to-severe chronic GVHD newly requiring 1 mg/kg/day prednisone were treated at 3 escalating dose levels (300 mg, 700 mg, and 1000 mg) of i.v. ofatumumab on days 1 and 14 of initial glucocorticoid therapy. Dose-limiting toxicity (DLT) was defined by grade 4 infusion reactions, related grade 4 constitutional symptoms, related grade ≥ 3 organ toxicities, or grade 4 neutropenia lasting > 14 days. A total of 12 patients (median age 54; range, 25 to 72) were treated (dose level 1: n = 3; level 2: n = 3; level 3: n = 6). At enrollment, overall chronic GVHD was moderate (n = 7) or severe (n = 5), with diverse organ involvement (skin: n = 8; mouth: n = 8; eye: n = 8; lung: n = 4; gastrointestinal: n = 3; liver: n = 5; genital: n = 2; joint/fascia: n = 5). Infusion of ofatumumab was well tolerated, and no DLT was observed. From the total number of adverse events (n = 29), possibly related adverse events (n = 4) included grade 1 fatigue, grade 1 transaminitis, and 2 infusion reactions (grades 2 and 3). Infectious complications were expected, and there were no cases of hepatitis B reactivation or progressive multifocal leukoencephalopathy. Ofatumumab in combination with prednisone is safe and a phase II examination of efficacy is ongoing. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
37. CARDIAC EVENTS AFTER ANTI-BCMA CHIMERIC ANTIGEN RECEPTOR T-CELL (IDECABTAGENE VICLEUCEL) FOR MULTIPLE MYELOMA.
- Author
-
Lee, Dae Hyun, Chandrasekhar, Sanjay Amrith, Jain, Michael, Hansen, Doris, Freeman, Ciara, Alsina, Melissa, Baz, Rachid, Puglianini, Omar Castaneda, Liu, Hien, Blue, Brandon, Davila, Marco L., Faramand, Rawan, Kumar, Abhishek, Shah, Bijal, Lazaryan, Aleksandr, Khimani, Farhad, Nishihori, Taiga, Bachmeier, Christina, Locke, Frederick, and Oliveira, Guilherme Henrique
- Subjects
- *
CHIMERIC antigen receptors , *MULTIPLE myeloma , *T cells - Published
- 2022
- Full Text
- View/download PDF
38. Sequence of novel agents in multiple myeloma: An instrumental variable analysis.
- Author
-
Baz, Rachid, Miladinovic, Branko, Patel, Amila, Ho, Viet Q., Shain, Kenneth H., Alsina, Melissa, Nishihori, Taiga, Ochoa-Bayona, Jose L., Sullivan, Daniel M., Dalton, William S., and Djulbegovic, Benjamin
- Subjects
- *
MULTIPLE myeloma , *LONGITUDINAL method , *INSTRUMENTAL variables (Statistics) , *PYRAZINES , *PHTHALIMIDES , *DRUG administration , *MULTIVARIATE analysis , *PATIENTS , *THERAPEUTICS - Abstract
Abstract: Lenalidomide and bortezomib have not been compared prospectively and are currently used in sequence for patients with multiple myeloma; however, it is unknown whether a sequence of administration could result in improved outcomes. We retrospectively reviewed electronic records of patients with multiple myeloma who had used both agents in sequence at our institution: 97 patients had lenalidomide first and 111 had bortezomib first. On multivariable analysis, the sequence of therapy was not associated with outcome. These findings were confirmed with instrumental variable analyses. Finally, use of bortezomib first was associated with improved survival for patients with baseline renal insufficiency. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
39. Survival Advantage of the Addition of Cell Therapy to Chemotherapy in Adult Patients with Relapsed AML After Allogeneic Hematopoietic Cell Transplantation
- Author
-
Kunter, Ghada M., Perkins, Janelle, Nishihori, Taiga, Locke, Frederick, Field, Teresa, Pidala, Joseph, Perez, Lia, Kharfan-Dabaja, Mohamed, Anasetti, Claudio, and Fernandez, Hugo
- Published
- 2013
- Full Text
- View/download PDF
40. Phase II Study of CD4+-Guided Pentostatin Lymphodepletion and Pharmacokinetically Targeted Busulfan as Conditioning for Hematopoietic Cell Allografting.
- Author
-
Kharfan-Dabaja, Mohamed A., Anasetti, Claudio, Fernandez, Hugo F., Perkins, Janelle, Ochoa-Bayona, Jose L., Pidala, Joseph, Perez, Lia E., Ayala, Ernesto, Field, Teresa, Alsina, Melissa, Nishihori, Taiga, Locke, Frederick, Pinilla-Ibarz, Javier, and Tomblyn, Marcie
- Subjects
- *
PHARMACOKINETICS , *HEMATOPOIETIC stem cell transplantation , *HOMOGRAFTS , *TACROLIMUS , *GRAFT versus host disease , *CHIMERISM , *ORGAN donors - Abstract
Abstract: One limitation of reduced-intensity preparative regimens is potential for graft failure. We have developed a regimen that targets CD4+ lymphodepletion to ensure early and durable engraftment. The primary endpoint was achievement of ≥50% CD3+ donor chimerism by day +28. Forty-two patients (median age, 53 years; range, 29 to 73 years) received pentostatin 4 mg/m2 i.v. on days −28, −21, and −14 when the CD4+ cell count was >100 cells/μL and on days −4 and −3 regardless of CD4+ level. Rituximab 375 mg/m2 was administered to patients with CD20+ malignancies on days −21, −14, −7, +1, and +8. Busulfan 200 mg/m2 i.v. was administered on days −4 and −2 at a dose to target a cumulative AUC dose of 16,000 (±10%) μmol·min/L. Graft-versus-host disease (GVHD) prophylaxis consisted of tacrolimus plus methotrexate in 86% of patients. Donors were matched-related (47%), matched unrelated (43%), or mismatched unrelated (10%). Chronic lymphocytic leukemia (45%) and follicular non-Hodgkin lymphoma (14%) were the most common diagnoses. Disease status at initiation of the preparative regimen was complete remission in 22%, partial response in 55%, and stable/progression in 24%. The median percent CD4+ cell count decrease from baseline (day −28) was 52% to day −21, 66% to day −14, 62% to day −7, and 91% to day 0. At day +28, all 42 patients (100%) had ≥50% CD3+ donor chimerism. No patient experienced graft failure. Overall response rate was 82% (complete remisson, 67%). The day +100 cumulative incidence of grade II-IV acute GVHD was 59% (grade III-IV acute GVHD, 19%), and the 2 year cumulative incidence of chronic GVHD was 69% (moderate/severe, 58%). Nonrelapse mortality was 2% at day +100 and 17% at 2 years. Two-year PFS was 55%, and OS was 68%. This regimen ensures durable engraftment, is effective against persistent disease, and results in relatively low mortality from causes other than relapse. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
41. Dysglycemia Following Glucocorticoid Therapy for Acute Graft-versus-Host Disease Adversely Affects Transplantation Outcomes
- Author
-
Pidala, Joseph, Kim, Jongphil, Kharfan-Dabaja, Mohamed A., Nishihori, Taiga, Field, Teresa, Perkins, Janelle, Perez, Lia, Fernandez, Hugo, and Anasetti, Claudio
- Subjects
- *
GLUCOSE , *METABOLISM , *GLUCOCORTICOIDS , *GRAFT versus host disease , *HEALTH outcome assessment , *FOLLOW-up studies (Medicine) , *THERAPEUTICS - Abstract
Disordered glucose metabolism is a common complication of glucocorticoid therapy for acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic cell transplantation (HCT). We aimed to examine the impact of dysglycemia on outcomes in 173 recipients of HCT treated with glucocorticoids for aGVHD. A total of 147 of these patients contributed data to a landmark analysis performed at 12 weeks post-HCT. Median aGVHD onset was 21 days (range: 5-79) after transplant. Median duration of glucocorticoid therapy was 381 days (range: 15-1632). Glucose values were obtained from glucocorticoid initiation date to death or last follow-up, resulting in 11,588 total values. The median (range) for each parameter were: maximum 292 mg/dL (128-694), minimum 75 mg/dL (34-142), average 142 mg/dL (86-327), and standard deviation 46 mg/dL (12-108). Baseline diabetes mellitus predicted significantly greater maximum, mean, and standard deviation. With median follow-up of 20 months (range: 3-55), median overall survival (OS) was 33.7 months (95% confidence interval [CI] 16.4—not reached). On multivariable analysis, maximum, average, or standard deviation of glucose values predicted OS and maximum or average glucose values predicted nonrelapse mortality (NRM). Minimum glucose values of (0-60 mg/dL) were associated with worsened OS and increased NRM. Those patients treated with insulin or oral agents suffered significantly worse OS and increased NRM compared to patients who did not need therapy. Finally, those with sustained maximum values >200 mg/dL despite treatment suffered worse OS and increased NRM. These data suggest an independent adverse effect of dysglycemia in patients treated with glucocorticoids for aGVHD, and argue for stringent glycemic control in this setting. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
42. Phase II Multicenter Study of Ofatumumab in Combination with Glucocorticoids As a Primary Therapy for Chronic Graft Versus Host Disease.
- Author
-
Lazaryan, Aleksandr, Lee, Stephanie, Arora, Mukta, Kim, Jongphil, Betts, Brian Christopher, Khimani, Farhad, Nishihori, Taiga, Bejanyan, Nelli, Liu, Hien, Kharfan-Dabaja, Mohamed A., Locke, Frederick L., Jain, Michael D., Davila, Marco L., Perez, Lia Elena, Mishra, Asmita, Ayala, Ernesto, Ochoa-Bayona, Leonel, Puglianni, Omar Castaneda, Faramand, Rawan, and Alsina, Melissa
- Subjects
- *
GRAFT versus host disease , *INTERLEUKIN-21 , *GLUCOCORTICOIDS , *IMMUNOSUPPRESSION - Abstract
B-cell homeostasis plays an important role in chronic GVHD (cGVHD). The safety and feasibility of anti-CD20 directed B-cell therapy with ofatumumab and glucocorticoids (GC) were previously established in a phase I trial. A total of 38 adult patients (pts) with moderate/severe cGVHD were enrolled in phase II trial at 3 academic US centers (02/2014-08/2018). Ofatumumab was given at 1000 mg IV on days 0 and 14 of initial 1 mg/kg/day prednisone (or equivalent) therapy. Primary endpoint was the overall (complete and partial) response rate (ORR) at 6 months as reported by the physician (MD). Baseline data are summarized in Table. Six-month ORR for 32 evaluable pts was 62.5% (95%CI, 44-79%) by MD report (15.6% CR; 46.9% PR) and by NIH2014 criteria (9.4% CR; 53.1% PR) with good inter-rater reliability (Cohen's kappa=0.73; discordant responses n=4). Given historical benchmark ORR of 60% at 6 months, the trial did not reach its primary endpoint (p =0.4) of 20% improvement with ofatumumab. Subsequent ORR per MD and NIH2014 were 42% and 31% at 12 months (kappa=0.6) and 36% and 32% at 24 months (kappa=0.9). GC discontinuation was successful in 45% and 54% of pts at 12 and 24 months (Figure 1A). Median follow up of survivors was 24 months (range, 0.7-46). Two-year OS and PFS were 74% and 72%. Failure-free survival (FFS) - composite outcome with death, relapse, and second-line immune suppression as events - was 53% at 12 months and 39% at 24 months. Second-line therapy was the most common failure event (13/22, Figure 1B). 14 non-fatal possibly related AEs occurred in 11 pts, including 5 SAEs in 3 pts. 17 infusion-related AEs (all ≤Gr2) occurred, but resolved with symptom management. Bacterial (13 events), fungal (8), and viral (26) infections were observed in 29%, 13%, and 40% of pts, respectively. 9 deaths occurred within 2 years, none of which was deemed related to study therapy. This multicenter phase II trial did not demonstrate statistical difference in 6 month ORR with ofatumumab+GC vs. GC-based historical benchmark in the frontline therapy of cGVHD. Data on predictors of response, patient-reported outcomes, and immune reconstitution will be presented at the meeting. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
43. Outcomes of Hematopoietic Cell Transplantation in Acute Promyelocytic Leukemia – a Single Institution Experience.
- Author
-
Hashmi, Hamza, Lancet, Jeffrey E., Mishra, Asmita, Sweet, Kendra, Komrokji, Rami, Fernandez, Hugo, Perez, Lia Elena, Khimani, Farhad, Elmariah, Hany, Pidala, Joseph A., Nieder, Michael L., Bejanyan, Nelli, List, Alan F., Anasetti, Claudio, and Nishihori, Taiga
- Subjects
- *
ACUTE promyelocytic leukemia , *CELL transplantation , *GRAFT versus host disease , *ALEMTUZUMAB - Abstract
Outcomes of patients with acute promyelocytic leukemia (APL) have improved; however, a significant number of patients still relapse despite receiving all-trans-retinoic acid (ATRA) and arsenic-based therapies. We present single institution outcomes of autologous (auto) and allogenic (allo) hematopoietic cell transplantation (HCT) in patients with relapsed APL. Outcomes in patients with relapsed APL who underwent either auto- or allo- HCT at Moffitt Cancer Center from 1990 to 2018 were reviewed utilizing the clinical data obtained from BMT Research & Analysis Information Network (BRAIN). Survival data were analyzed using Kaplan-Meier estimates. Autologous HCT Cohort: A total of 15 received auto-HCT with a median age at HCT of 39 (range, 21-60) years. Only 3/8 patients with known disease risk at time of diagnosis had high risk disease (high=3, low=5). Disease status at HCT were first complete remission (CR1) in 5 (33%) and CR2 in 10 (67%). All 8 patients who had minimal residual disease evaluation had negative PCR for PML-RARA. The median progression-free survival (PFS) for auto HCT was 12.9 (95% confidence interval (CI): 1.2-24.8) years. With a median follow up of 45.1 months for surviving patients, overall survival (OS) for auto HCT was 12.9 (95%CI: 0-27.8) years. A total of 9 patients received allo HCT with a median age at HCT of 43 (range, 22-56) years. All six patients with known disease risk at time of diagnosis were either intermediate (n=2) or high risk disease (n=4). Disease status at allo HCT was CR2 in 1, CR3 in 6, and two had refractory disease. Two patients had prior auto HCT. 5/6 patients who had minimal residual disease evaluation had negative PCR for PML-RARA. Donor type was HLA-identical sibling=5; one antigen-mismatched sibling=1; HLA-matched unrelated donor=2; related haploidentical=1. Conditioning regimen intensity was myeloablative in six and reduced intensity in three of the patients. Six patients received tacrolimus-based graft-versus-host disease (GVHD) prophylaxis. The median PFS for allo HCT was 11.9 (95%CI: 0-24.1) months. With a median follow up of 48.2 months for surviving patients, OS for allo HCT was 14.2 (95%CI: 6.5-21.9) months. In our single center analysis, auto HCT resulted in a durable remission and prolonged survival. Outcomes after allo HCT were suboptimal primarily due to their heavily pretreated condition and chemotherapy resistant disease. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
44. Identification of Early Predictive Markers of Toxicity and Efficacy in Patients with DLBCL Treated with Axicabtagene Ciloleucel.
- Author
-
Faramand, Rawan, Jain, Michael D., Staedtke, Verena, Bai, Renuyan, Kotani, Hiroshi, Reid, Kayla, Lee, SaeBom, Chavez, Julio C., Shah, Bijal D., Nishihori, Taiga, Lazaryan, Aleksandr, Khimani, Farhad, Liu, Hien, Bachmeier, Christina A., Dam, Marian, Brandjes, Brigett, Mullinax, John E., Gonzalez, Ricardo, Wang, Xuefeng, and Hussaini, Mohammed
- Subjects
- *
FERRITIN , *T cells , *B cells , *CELLULAR therapy , *CANCER treatment , *NEUROTOXICOLOGY , *CLINICAL trials , *ALEMTUZUMAB - Abstract
CAR T cells have been extensively investigated using constructs targeting CD19+ B cells for lymphoid malignancies demonstrating efficacy (Neelapu NEJM 2018; Schuster NEJM 2018). One of the main challenges of adoptive T cell therapy are immune mediated toxicities of cytokine release syndrome (CRS) and neurotoxicity (NT). Despite impressive objective response rates, durable responses are only seen in approximately 40% of patients treated in the pivotal axicabtagene ciloleucel (axi-cel) and tisagenlecleucel trials, highlighting the need for better understanding of the mechanisms of toxicity and efficacy. We aimed to evaluate the association of early biomarkers with severe toxicity and day 90 outcomes in patients treated with commercial axi-cel in a real world setting. Seventy-five patients treated with commercial axi-cel were included in this analysis. Baseline characteristics are summarized in Table 1. Patient serum samples were collected at baseline (within 30 days of conditioning chemotherapy), and then daily thereafter starting at the day of axi-cel infusion. Serum cytokine samples were analyzed using the Ella multiplex assay system. Cytokines analyzed include IL1b, IL2, IL6, IL15, TNFa, IFNg, Angiopoietin 1 and 2, as well as CRP and ferritin. Toxicities were graded daily using ASTCT consensus guidelines and retrospectively confirmed. Outcomes were evaluated at day 90 by the treating physician according to the International Working Group Response Criteria for Malignant lymphoma. P values were calculated using Wilcoxon rank sum test. We observed that baseline levels of CRP (p=0.0018) and Angiopoietin 2/1 ratio (p=0.0092) were associated with grade ≥3 [n=16] neurotoxicity Figure 1A-B). Baseline elevated levels of CRP (p=0.0413) and Ferritin (0.0264) were associated with more grade ≥3 CRS [n=16] (Figure 1C-D). Baseline elevated levels of CRP(p=0.0016), ferritin(p=0.0096) and IL6 (p=0.0029) were associated with poor outcomes at D90 defined as stable disease, progressive disease or death (Figure 1E-G). We demonstrate that baseline biomarker profile can identify patients at highest risk of developing severe toxicity and/or and treatment resistance highlighting the need to validate these findings in prospective studies. Patients in this poor outcome cohort may benefit from clinical trials evaluating prophylactic agents or more combination therapies to ameliorate severe toxicities or increase response rates. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
45. Hypofibrinogenemia in Patients Receiving CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Large B Cell Lymphoma: A Single Institution Experience.
- Author
-
Hashmi, Hamza, Mirza, Abu-Sayeef, Darwin, Alicia, Logothetis, Constantine, Garcia, Franco, Kommalapati, Anuhya, Bachmeier, Christina A., Benson, Kaaron, Chavez, Julio C., Shah, Bijal D., Pinilla-Ibarz, Javier, Khimani, Farhad, Lazaryan, Aleksandr, Liu, Hien, Davila, Marco L., Nishihori, Taiga, Jain, Michael D., and Locke, Frederick L.
- Subjects
- *
CHIMERIC antigen receptors , *RITUXIMAB , *B cells , *BLOOD coagulation factors , *T-cell lymphoma , *FIBRINOGEN , *LYMPHOMAS - Abstract
Hypofibrinogenemia can occur after Chimeric Antigen Receptor (CAR) T-cell therapy and is sometimes associated with cytokine release syndrome. Hypofibrinogenemia is associated with increased risk of bleeding as well as thrombosis. Limited literature exists on the incidence, complications and management of hypofibrinogenemia after CAR T-cell therapy. We analyzed medical records on 148 patients who received CD19-directed CAR T-cell therapy for large B-cell lymphomas between 05/2015 and 09/2019. All patients who had at least one serum fibrinogen level measured in the first 30 days after CAR T-cell infusion were included in the analysis. All patients with serum fibrinogen < 200 mg/dL [lowest normal value] had data collected on abnormalities in other coagulation parameters including PTT, PT, INR at the time of nadir serum fibrinogen level. Out of 148 patients, 35 had at least one serum fibrinogen level measured in the first 30 days after CAR T-cell infusion. Nadir serum fibrinogen was < 200 mg/dl in 15/35 patients: 0-100 mg/dl in 9/15 and 100-200 mg/dl in 6/15. At the time of nadir fibrinogen level, 2/15 patients had abnormalities seen in the other 3 coagulation parameters. Of the 15 patients that had serum fibrinogen level < 200 mg/dl, four had a bleeding event and one had a thrombotic event within first 30 days after CAR T-cell infusion but none of these patients had a low fibrinogen level at the time of the bleed. Given concern for increased risk of bleeding, patients with serum fibrinogen level less than 100 mg/dl were given cryoprecipitate infusions. Details of the abnormalities in the coagulation parameters are highlighted in the table. This study describes in detail, hypofibrinogenemia seen in patients treated with CD19-directed CAR T-cell therapy in lymphoma. None of the patients experienced a major bleeding or thrombotic event with low serum fibrinogen level. These descriptive data may be used by clinicians to inform their management of hypofibrinogenemia seen in CAR T-cell patients. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
46. Incidence and Management of Effusions during CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Receptor Therapy in B-Cell Lymphoma: A Single Institution Experience.
- Author
-
Mirza, Abu-Sayeef, Hashmi, Hamza, Darwin, Alicia, Garcia, Franco, Kommalapati, Anuhya, Logothetis, Constantine, Bachmeier, Christina A., Chavez, Julio C., Shah, Bijal D., Pinilla-Ibarz, Javier, Khimani, Farhad, Lazaryan, Aleksandr, Liu, Hien, Davila, Marco L., Nishihori, Taiga, Locke, Frederick L., and Jain, Michael D.
- Subjects
- *
CHIMERIC antigen receptors , *EXUDATES & transudates , *INTERLEUKIN-27 , *ASCITIC fluids , *IMPLANTABLE catheters , *LYMPHOMAS , *B cells - Abstract
In patients with lymphoma, third space fluid accumulations may develop or worsen during cytokine release syndrome (CRS) associated with chimeric antigen receptor (CAR) T-cell therapy. Pre-existing symptomatic pleural effusions were excluded by the ZUMA-1 trial of axicabtagene ciloleucel (axi-cel) for large B cell lymphoma (LBCL) and variants. The optimal management of effusions that develop before or after axi-cel infusion in LBCL is unknown. We performed a single center retrospective study evaluating 148 patients receiving CD19 CAR T-cell therapy for LBCL between 05/2015 and 09/2019. We identified all patients who developed pleural, pericardial and peritoneal effusions before (pre-CAR-T) or during the first 30 days after CAR T-cell infusion (post-CAR-T). Clinically relevant effusions were considered symptomatic based upon physician documentation. Total effusions and symptomatic effusions were noted in 24% (36/148) and 18% (27/148) of patients, respectively. Among 27 patients with symptomatic effusions, 59% (16/27) were pre-CAR-T effusions, 52% (14/27) persisted after day 30, and 44% (12/27) were malignant effusions. Overall, 67% of symptomatic effusions (18/27) were managed with diuretics, 44% (12/27) with a therapeutic thoracentesis or paracentesis and 33% (9/27) were observed with only supplemental oxygen provided. Six patients required pleural or abdominal catheters with a median indwelling duration of 54 (range, 29, 202) days, although 2 of these patients passed away with these indwelling catheters. Among symptomatic effusions developing only post-CAR-T (n=11), time to onset of effusion was median of 5 (range, 2-11) days and none of these patients required interventional drainage. Table 1 differentiates between effusions based on whether they were present (n = 19) or not (n = 17) prior to CAR T cell infusion. Nearly half of all effusions diagnosed in patients receiving CAR T cell therapy develop after infusion but most can be medically managed. Patients with pre-CAR-T effusions may require procedural drainage or indwelling catheters, as these effusions may persist beyond the acute CRS period. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
47. Delayed CD4+ T-Cell but Faster B-Cell Immune Reconstitution after Ptcy-Based Compared to Conventional Gvhd Prophylaxis after Allogeneic Transplantation.
- Author
-
Ranspach, Peter, Zhou, Jun-Min, Pidala, Joseph A., Nishihori, Taiga, Nieder, Michael L., Elmariah, Hany, Faramand, Rawan, Lazaryan, Aleksandr, Baluch, Aliyah, Mishra, Asmita, Perez, Lia Elena, Ochoa, Leonel, Liu, Hien, Davila, Marco L., Jain, Michael D., Locke, Frederick L., Alsina, Melissa, Kim, Jongphil, Bejanyan, Nelli, and Khimani, Farhad
- Subjects
- *
CARDIAC pacing , *GRAFT versus host disease , *CELL transplantation , *PREVENTIVE medicine , *VIRUS diseases , *ALEMTUZUMAB , *TRANSPLANTATION of organs, tissues, etc. , *ANTIBIOTIC prophylaxis - Abstract
Post-transplant cyclophosphamide (PTCY) is being increasingly used for graft-versus-host disease (GVHD) prophylaxis after hematopoietic cell transplantation (HCT) across various donor types. However, immune reconstitution after PTCY-based vs. conventional GVHD prophylaxis has not been well studied. We evaluated the pace of immune reconstitution (CD4+ T-cell, CD8+ T-cell, NK-cell and B-cell) at 3 months, 6 months and 1 year post-HCT in 583 adult patients receiving myeloablative (n=223) or reduced intensity conditioning (n=360) HCT (2012-2018). Haploidentical (Haplo; n=75) and 8/8 HLA-matched unrelated (MUD, n=508) donor types were included. GVHD prophylaxis was PTCY-based in 75 Haplo and 38 MUD (MUD-PTCY) HCT, while tacrolimus/methotrexate (TAC/MTX) was used in 89 and TAC/Sirolimus (TAC/SIR) in 381 MUD HCT. Clinical outcomes including viral infections, non-relapse mortality (NRM) and overall survival (OS) were compared across all four treatment groups. The recovery of absolute total CD4+ T-cell count after Haplo-PTCY and MUD-PTCY was significantly lower compared to MUD TAC/MTX or MUD TAC/SIR throughout 1 year of HCT (Figure). In contrast, CD19+ B-cell recovery at 6 months and thereafter was more rapid after Haplo-PTCY and MUD-PTCY HCT in comparison to MUD TAC/MTX and MUD TAC/SIR. In subgroup analysis compared to MUD TAC/MTX HCT, total CD8+ T-cell or NK-cell recovery was not significantly different after Haplo-PTCY or MUD-PTCY HCT. However, patients receiving MUD TAC/SIR vs. MUD TAC/MTX had significantly slower reconstitution of total CD8+ T-cells up to 6 months and CD19+ B-cells at 1 year of HCT, but no significant differences in CD4+ T-cell or NK-cell recovery. The distribution of recipient CMV serostatus was similar in all four groups: 72% in Haplo-PTCY, 62 % in MUD-PTCY HCT, 68% in MUD TAC/MTX and 63% in MUD TAC/SIR (p =0.11). Cumulative incidence of CMV reactivation/infection at 1-year of HCT was higher in patients receiving Haplo-PTCY (39.6%) or MUD TAC-MTX (37.7%) compared to those receiving MUD-PTCY (27.0%) or MUD TAC/SIR (22.8%; p <0.01). Whereas the incidence of EBV reactivation/infection was lower in patients receiving PTCY-based GVHD prophylaxis (5.2% in Haplo-PTCY and 8.1% in MUD-PTCY) as compared to patients receiving MUD TAC/MTX (19.7%) or MUD TAC/SIR (20.5%, p <0.01). The incidences of HHV6, BK- and other viruses were similar between the groups. Overall, the treatment groups had comparable NRM (p =0.27) and OS outcomes (p =0.78). Our data demonstrate that the pattern of immune reconstitution after HCT is different after PTCY-based vs. conventional GVHD prophylaxis with delayed total CD4+ T-cell but more rapid B-cell recovery after PTCY-based GVHD prophylaxis. The rates of CMV and EBV viral infections were different across the donor types. However, these differences had no significant influence on NRM or survival after HCT. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
48. Survival of Older Patients with AML and MDS after Allogeneic Hematopoietic Transplantation Is Best Determined By Combining Disease Risk and Comorbidity Indices.
- Author
-
Asghari, Hannah, Mo, Qianxing, Naqvi, Syeda Mahrukh, Lazaryan, Aleksandr, Davila, Marco L., Nishihori, Taiga, Khimani, Farhad, Mishra, Asmita, Perez, Lia Elena, Elmariah, Hany, Liu, Hien, Nieder, Michael L., Fernandez, Hugo, Pidala, Joseph A., Anasetti, Claudio, and Bejanyan, Nelli
- Subjects
- *
ACUTE myeloid leukemia treatment , *SURVIVAL analysis (Biometry) , *COMORBIDITY , *HEMATOPOIETIC stem cell transplantation , *HEMATOLOGIC malignancies - Abstract
Disease Risk Index (DRI) and Hematopoietic Cell Transplant Comorbidity Index (HCT-CI) are independently validated and powerful pretransplant prognostic tools for overall survival (OS) of patients receiving allogeneic HCT (alloHCT) for hematological malignancies. Here we examined the prognostic significance of the DRI in conjunction with HCT-CI on OS among 341 elderly patients (≥60 years old) with AML (n=214) and MDS (n=127) who received alloHCT from 2005 to 2016. The median age at alloHCT for all patients was 66 (range, 60-76) years: 42% were age 60-64, 43% age 65-69 and 15% age ≥70. DRI classified patients as low/intermediate risk (LR/IR DRI, 63%) or high/very high risk (HR DRI, 37%). Nearly half of the patients had many comorbidities (HCT-CI ≥3) and 30% of all patients had lower Karnofsky Performance Status score (KPS <90%) at transplant. Myeloablative conditioning was used in 58% of all patients and 58% received matched unrelated donor, followed by matched related donor (26%) or mismatched donor (16%) alloHCT. Majority of patients (94%) received a peripheral blood allograft and 67% of all patients were CMV seropositive. There were no significant differences between LR/IR DRI group and HR DRI group in regards to any patient or transplant related characteristics examined. OS at 2 years was 50% (45-56%) for the entire cohort. When combined effect of DRI and HCT-CI was considered, overall mortality risk significantly increased with higher HCT-CI within each DRI group, resulting in 2-year OS of 66.2% in LR/IR DRI+HCT-CI 0-2 vs. 56.2% in LR/IR DRI+HCT-CI ≥3 vs. 47.1% HR DRI+HCT-CI 0-2 vs. 34.8% HR DRI+HCT-CI ≥3 groups (p <0.0001) (Figure). In multivariate Cox regression analysis, after adjusting for age, CMV serostatus and conditioning intensity the HR DRI (hazard ratio (HR) =2.2, 95% CI 1.6-3.0; p <0.001) and HCT-CI ≥3 (HR=1.5, 95% CI 1.0-2.1; p =0.04) were the only factors independently predictive of higher overall mortality. Increasing age (HR=1.3, 95% 0.9-1.9 CI; p =0.13 for age 65-69, and HR=1.0, 95% 0.6-1.6 CI; p =0.097 for age ≥70) and diagnosis (HR=0.9, 95% 0.6-1.3 CI; p =0.6 for MDS) had no significant impact on survival. Our findings suggest that most elderly patients with AML and MDS benefit from potentially curative alloHCT. Survival was worse for patients with combined high risk DRI and many comorbidities (HR DRI+ HCTCI ≥3). Thus, combining DRI and HCT-CI can serve as an effective pre-HCT tool to prognosticate survival after alloHCT. Age alone should not be a limiting factor in transplant decision making in otherwise eligible patients with AML and MDS. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
49. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Chronic Myelomonocytic Leukemia: A National Cancer Database Analysis.
- Author
-
Dholaria, Bhagirathbhai, Kumar, Ambuj, Ayala, Ernesto, Kharfan-Dabaja, Mohamed A, and Nishihori, Taiga
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *LEUKEMIA treatment , *CANCER diagnosis , *SURVIVAL analysis (Biometry) , *FOLLOW-up studies (Medicine) - Abstract
Introduction Allo-HCT is the only potentially curative therapy for Chronic Myelomonocytic Leukemia (CMML). Objectives To study the impact of allo-HCT on survival of CMML patients. Method We compared the survival outcomes of patients who received (or not) an allo-HCT as a part of their front-line treatment strategy using The National Cancer Database (NCDB) from 2004-2015. Results A total of 8,208 CMML patients were identified, but only 153 were allografted. Median follow-up of survivors was 33.6 months (95% CI=39.6-42.6). Allo-HCT recipients were more likely to be younger, of the male gender, had lower Charlson/Deyo co-morbidity score, had a higher median household income, being treated at an academic facility and having private insurance (Table 1). For survival analysis, we excluded 4484 patients who did not receive front-line therapy to better assess impact of allo-HCT on overall survival (OS). The median OS for patients who received chemotherapy alone or chemotherapy + allo-HCT was 13.3 (95% CI=12.7-14.0) months and 47.4 (14.5-80.4) months, respectively (p <0.001, Figure 1) After adjusting for baseline characteristics using Cox-regression modeling, allo-HCT results in better OS (HR=0.45, 95% CI=0.35-0.59, p <0.01). Age, high comorbidity score, treatment at community facility and year diagnosis before 2009 were associated with poor OS (Table 2). Positive impact of Allo-HCT on OS was maintained in a 6-month landmark analysis after excluding patients who died or were lost follow-up within 6 months from diagnosis (HR= 0.59, 95% CI=0.45-0.77, p <0.01). Conclusion Allo-HCT is an independent prognostic factor for improved OS in CMML. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
50. The Effect of Mycophenolate Mofetil Dose per Kilogram on Clinical Outcomes of Allogeneic Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide.
- Author
-
Elmariah, Hany, Laborde, Jose, Kim, Jongphil, Gonzalez, Rebecca, DiMaggio, Elizabeth, Nishihori, Taiga, Mishra, Asmita, Perez, Lia Elena, Liu, Hien, Khimani, Farhad, Ochoa-Bayona, Jose, Faramand, Rawan, Baluch, Aliyah, Nieder, Michael L., Lazaryan, Aleksandr, Sullivan, Daniel, Pidala, Joseph A., and Bejanyan, Nelli
- Subjects
- *
MYCOPHENOLIC acid , *HEMATOPOIESIS , *BODY mass index , *CELL transplantation , *GRAFT versus host disease , *TRANSPLANTATION of organs, tissues, etc. ,BONE marrow examination - Abstract
Mycophenolate mofetil (MMF) dose/kg can influence clinical outcomes of allogeneic hematopoietic cell transplantation (HCT) including acute graft-versus-host disease (GVHD) (Harnicar BBMT 2015; Bejanyan BBMT 2018). When used for GVHD prophylaxis in conjunction with post-transplant cyclophosphamide (PTCy), MMF is generally dosed at 15 mg/kg three times daily (capped at a maximum of 3 g/day) and combined with either tacrolimus or sirolimus. Thus, many adults receive the maximum dose and a variable dose/kg of MMF. We sought to investigate the impact of MMF dose/kg on clinical outcomes of HCT in the setting of PTCy-based GVHD prophylaxis, where the effect of MMF dose/kg is unknown. Included are 112 consecutive adult patients with hematologic malignancies who received myeloablative (n=70) or reduced intensity (n=42) HCT at the Moffitt Cancer Center between 2012-2018 with T-cell replete peripheral blood stem cells (n=94) or bone marrow (n=18). GVHD prophylaxis consisted of PTCy/MMF and either tacrolimus (n=57) or sirolimus (n=55). MMF dose relative to patient actual body weight (mg/kg/day), was stratified by tertiles into low (<30 mg/kg/day, n=31), intermediate (30-40 mg/kg/day, n=45) and high (>40 mg/kg/day, n=36). The median age at transplant was 57.8 (range: 21-75) years. Median follow-up was 12 months (range: 0.3-39). Donors were haploidentical related (n=74), mismatched unrelated (n=26), and matched related/unrelated (n=12). MMF dose groups had similar characteristics, except the low dose group having a higher proportion of males (p<0.01), higher body mass index (p<0.01), and patients receiving <3g/day MMF (p<0.01). Cumulative incidence rate (CIR) of neutrophil engraftment was 96% and of platelet engraftment was 89% for all patients. For the entire cohort, CIR was 41% for grade II-IV and 11% for grade III-IV acute GVHD at day 100 and 46% for chronic GVHD at 2-years. MMF dose had no significant effect on acute (Figure 1) or chronic GVHD (Table). Probability of 2-year non-relapse mortality (NRM) was 17% and relapse was 31% for all patients. Corresponding 2-year overall survival (OS) was 60% and disease-free survival (DFS) was 52% (Figure 2). While MMF dose did not significantly influence NRM, relapse or OS, we observed significantly better DFS in patients receiving intermediate vs. low weight-based MMF dose (HR=0.5, CI: 0.25-0.998, p=0.049). In patients receiving PTCy based GVHD prophylaxis, MMF dose/kg had no significant effect on GVHD. However, lower MMF dose/kg was associated with worse DFS. This study suggests that <30 mg/kg/day may lead to inferior clinical outcomes. Larger studies are needed to confirm these findings. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.